GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac

GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.